DOSING REGIMEN FOR MULTIPLE SCLEROSIS

(19)

(11)

EP 3 199 172 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	11.10.2017 Bulletin 2017/41

(43)	Date of publication:
	02.08.2017 Bulletin 2017/31

(21)	Application number: 17157735.6

(22)	Date of filing: 19.08.2010

(51)

International Patent Classification (IPC):

A61K 38/02^(2006.01)
A61P 25/28^(2006.01)
A61K 9/00^(2006.01)

A61K 38/16^(2006.01)
A61K 38/07^(2006.01)
A61K 31/785^(2006.01)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NO PL PT RO SE SI SK SM TR
	Designated Extension States:
	BA ME RS

(30)

Priority:

20.08.2009 US 274687 P
11.02.2010 US 337612 P

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	17153450.6
	13166080.5 / 2630962
	10810282.3 / 2405749

(71)	Applicant: Yeda Research and Development Co., Ltd.
	76100 Rehovot (IL)

(72)	Inventor:
	KLINGER, Ety 39930 Tel Aviv (IL)

(74)	Representative: D Young & Co LLP
	120 Holborn London EC1N 2DY London EC1N 2DY (GB)


	Remarks:
	This application was filed on 23-02-2017 as a divisional application to the application mentioned under INID code 62.

(54)	DOSING REGIMEN FOR MULTIPLE SCLEROSIS

(57) A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a tharapoufiaally effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.